Cardiopulmonary Interactions in Patients With Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate cardiopulmonary interactions in patients with heat failure

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictors of an Unfavorable Outcome in Patients With Heart Failure

NCT04753814

Heart Failure

COMPLETED NA

Comprehensive Medication Monitoring on Heart Failure Patient Outcomes

NCT03519477

Heart Failure，Congestive

WITHDRAWN NA

Finding Early Predictors of Myocardial Dysfunction

NCT02026154

Hypertension Heart Failure

COMPLETED

Role of Comorbidities in Chronic Heart Failure Study

NCT02922478

Heart Failure Comorbidity Osteoporosis +3 more

COMPLETED

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

NCT07008729

Chronic Heart Failure Heart Transplant Recipient Left Ventricular Assist Device

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure is one of the most common diseases, especially in ageing populations, affecting ≥10% of persons 70 years of age or older. There is a growing body of evidence that dyspnea in patients with heart failure is not only related to low cardiac output and pulmonary venous congestion, but also to functional and structural alterations of the lungs.Pulmonary hypertension is a well-known complication of heart failure, but recent evidence suggests that the alveolo-capillary membrane is also affected, at least in subgroups of patients with heart failure.

Damage to the alveolo-capillary membrane is reflected by a low diffusion capacity of the lungs for carbon monoxide (DLCO).

In this study we aim to describe the alteration of lung function and obtain morphometric data of the capillary bed of patients with heart failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Pulmonary Hypertension Heart Failure With Reduced Ejection Fraction Heart Failure With Normal Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung Biopsy during LVAD Implantation

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent prior to initiation of any study-mandated procedures
* Male or female ≥40 years at screening
* Confirmed diagnosis of HFpEF (Heart failure with preserved ejection fraction), HFmrEF (heart failure with mid range ejection fraction) or HFrEF (Heart failure with reduced ejection fraction) in New York Heart Association (NYHA) Functional Class II, III or IV

Exclusion Criteria

* Significant lung disease according to the judgment of the investigator; as a rule, the total lung capacity (TLC) should be \>70% of the predicted value and the forced expiratory volume in 1 second (FEV1) should be \>60% of the predicted value
* Significant co-morbidities expected to limit life expectancy to less than 2 years, according to the judgment of the investigator

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No